Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psychiatric, cardiovascular and quality-of-life impact of TSH-suppressive levothyroxine therapy after thyroidectomy for differentiated papillary thyroid carcinoma
2009-018277-31Phase 4Active
- Sponsor
- CHU Nîmes
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of levothyroxine sodium in papillary thyroid cancer (PTC), sponsored by CHU Nîmes. Primary endpoint: Prevalence and severity of anxiety disorders (STAI score). Started Feb 2010; status: active.
02
Drugs
levothyroxine sodium
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on 2009-018277-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018277-31.